Keyphrases
Interleukin-23 (IL-23)
100%
Targeted Therapy
100%
Ustekinumab
100%
Pyoderma Gangrenosum
100%
Chronic Inflammatory Diseases
14%
Pathophysiology
14%
Protein Level
14%
Inflammatory Bowel Disease
14%
Psoriasis
14%
Pathogenic Mechanism
14%
Inflammation
14%
Crohn's Disease
14%
Tissue Sampling
14%
Healing
14%
Transcriptional Level
14%
Monoclonal Antibody
14%
Therapeutic Agents
14%
Targeted Treatment
14%
Interleukin-17 (IL-17)
14%
Initial Manifestation
14%
Sample Analysis
14%
Inflammatory Infiltrate
14%
Neutrophil Recruitment
14%
P40 Subunit
14%
6-month Follow-up
14%
Neutrophil Infiltration
14%
Medicine and Dentistry
Targeted Therapy
100%
Ustekinumab
100%
Pyoderma gangrenosum
100%
Interleukin 23
100%
Diseases
28%
Pathophysiology
14%
Psoriasis
14%
Crohn's Disease
14%
Inflammatory Bowel Disease
14%
Therapeutic Agent
14%
Inflammatory Infiltrate
14%
Interleukin 17
14%
Monoclonal Antibody
14%
Neutrophil
14%
Pharmacology, Toxicology and Pharmaceutical Science
Interleukin 23
100%
Ustekinumab
100%
Pyoderma gangrenosum
100%
Diseases
28%
Inflammatory Bowel Disease
14%
Inflammatory Infiltrate
14%
Pathophysiology
14%
Inflammation
14%
Monoclonal Antibody
14%
Psoriasis
14%
Crohn's Disease
14%
Interleukin 17
14%
Immunology and Microbiology
Interleukin 23
100%
Ustekinumab
100%
Monoclonal Antibody
14%
Inflammatory Bowel Disease
14%
Crohn's Disease
14%
Neutrophil
14%
Interleukin 17
14%
Biochemistry, Genetics and Molecular Biology
Ustekinumab
100%
Interleukin 23
100%
Monoclonal Antibody
14%
Interleukin 17
14%